What is the correct technique and dosing for intravenous adenosine administration in an adult with regular narrow‑complex supraventricular tachycardia and no contraindications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How to Give Inj Adenosine

Administer adenosine as a 6 mg rapid IV bolus through the most proximal IV site possible (as close to the heart as feasible), injected over 1-2 seconds, immediately followed by a rapid 20 mL saline flush, with the patient supine. 1

Initial Dose and Administration Technique

  • First dose: 6 mg as a rapid IV bolus over 1-2 seconds 1
  • Critical technique points:
    • Use the most proximal IV site available (closest to the heart) 1
    • Inject rapidly over 1-2 seconds—speed is essential due to adenosine's extremely short half-life (<10 seconds) 1
    • Immediately follow with rapid saline flush (typically 20 mL) 1
    • Patient should be supine during administration 2

Subsequent Dosing if Initial Dose Fails

  • If no response within 1-2 minutes: Give 12 mg rapid IV bolus 1
  • Can repeat the 12 mg dose one additional time if needed 1
  • The 18 mg bolus dose has been reported as safe in refractory cases 1

Critical Timing and Monitoring

  • Continuous ECG monitoring is mandatory during administration 1
  • Average time to termination of tachycardia is 30 seconds after injection 3
  • Success rates: 57.4% with 6 mg, increasing to 93.4% after the 12 mg dose 3

Important Caveats and Pitfalls

Central vs. Peripheral Administration:

  • If using a central line, start with only 3 mg (not 6 mg), as central administration requires significantly lower doses 4
  • 77% of patients respond to 3 mg centrally vs. only 37% peripherally 4

Patient Factors Affecting Dosing:

  • Higher body weight reduces first-dose success—patients weighing >80 kg have lower conversion rates with standard 6 mg dosing 5
  • Patients with impaired venous return (right heart failure, pulmonary hypertension) may require higher doses due to delayed drug delivery 6
  • Methylxanthines (caffeine, theophylline, aminophylline) antagonize adenosine—higher doses may be needed 1, 7
  • Dipyridamole potentiates adenosine—use lower doses or avoid 1, 7

Safety Considerations:

  • Have resuscitation equipment immediately available 2, 1
  • Side effects (flushing, chest discomfort, dyspnea) occur in 30-36% but last <1 minute 3, 1
  • Do not use in patients with second/third-degree AV block, sick sinus syndrome, asthma/bronchospasm, or known hypersensitivity 7
  • Can precipitate atrial fibrillation with rapid ventricular response in pre-excitation syndromes—have cardioversion ready 1

Post-Conversion Management:

  • Atrial or ventricular premature complexes immediately after conversion may reinitiate tachycardia 1
  • Consider antiarrhythmic prophylaxis if immediate recurrence occurs 1

Alternative if Adenosine Fails

If adenosine fails after maximum dosing (6 mg → 12 mg → 12 mg), proceed to:

  • Synchronized cardioversion if hemodynamically unstable 2, 1
  • IV calcium channel blockers (diltiazem or verapamil) or beta-blockers if stable 2

The arm elevation technique (raising arm to 90° for 10 seconds after injection) shows no significant benefit over standard technique 8.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.